In this Issue
Pushing Past a Numerical Value With Advances in Glaucoma Research and Care
Associate Medical Editor’s Page
By Arsham Sheybani, MD
Researchers studied postoperative phenomena and outcomes.
By Kateki Vinod, MD; and Rachel Lee, MD
What caused the IOP to rise dramatically 2 years after glaucoma surgery?
By Douglas J. Rhee, MD; Thomas Patrianakos, MD; and Angela Turalba, MD
RESIDENTS & FELLOWS
Waxing nostalgic while welcoming new tech to glaucoma.
By Vincent P. Moscato, MD
A review of the pros and cons of premium IOLs in glaucomatous eyes.
By Susan Liang, MD
A closer look at the challenges of achieving health equity around the world.
By Zaiba Malik, MD
Researchers studied motor vehicle accidents among patients with glaucoma.
By Sheryl S. Wizov, COA; Eric J. Shiuey, MS; and Jonathan S. Myers, MD
IOP is just one piece of a complex puzzle.
By Peter T. Chang, MD; Kevin L. Shen, MD; and Ronak S. Patel, MD
New drug targets and approaches to designing clinical trials hold promise for the development of neuroprotective therapies for glaucoma.
By Wendy W. Liu, MD, PhD; and Milica A. Margeta, MD, PhD
Out with the old paradigm and in with the new.
By Jeffrey L. Goldberg, MD, PhD
Optic nerve regeneration is becoming a reality.
By Yuqin Yin, MD, PhD; and Larry I. Benowitz, PhD
Is a curative or preventive therapy on the horizon?
By Janey L. Wiggs, MD, PhD
Pointers for shortening the learning curve and improving image quality.
By Gagan Kalra; and Parul Ichhpujani, MS
Two ophthalmologists from different generations weigh in on finding happiness and balance in their careers.